NICE

What are biosimilars and generics? And how could they save the NHS up to £1 billion over five years? Our explainer breaks it down: indepth.nice.org.uk/biosimilars-an…

Almost 30,000 people with the breathing condition COPD are set to benefit after we recommended a new targeted treatment that can be taken at home. Learn more about dupilumab: nice.org.uk/guidance/ta114…

Better data means more accurate assessments, helping ensure NHS resources go to treatments that make the biggest difference to people's lives. We welcome the new EQ-5D-5L value set for the UK as announced by @EuroQol. Sophie Cooper explains more: nice.org.uk/news/blogs/bet…

We're at #REWIRED26 in Birmingham. Developing or adopting digital tech? Find us at stand F01 discuss how we can help. 👉Explore support: nice.org.uk/what-nice-does…

Thousands of people with head and neck cancer are set to benefit after we recommended a new treatment that can be taken before and after surgery. Find out more about pembrolizumab: nice.org.uk/guidance/indev…

"Fear of a second stroke doesn't dictate my life anymore." After his stroke, Peter lived with uncertainty. An implantable cardiac monitor detected atrial fibrillation after a year of monitoring. He got the right treatment and his life back. Peter's story indepth.nice.org.uk/PetersStory/in…

The Health Economics Methods Advisory group (HEMA) is an international collaboration to research and evaluate health technology assessment methods. Join a webinar to discuss the findings of its first report on Monday 23 March @CDA_AMC @icer_review us02web.zoom.us/webinar/regist…

Earlier this week we published final guidance recommending ruxolitinib for treating non-segmental vitiligo in people 12 years and over⬇️ nice.org.uk/guidance/ta1140

Today’s new guidance has been welcomed by patients and charities, including the Rose Woodward, CEO of @ACTION4KC, who was a member of our guideline committee.

We have also published our first quality standard covering kidney cancer. It sets out a series of statements describing high-quality care in priority areas for improvement. Read more: nice.org.uk/guidance/qs215…

First kidney cancer guideline published by NICE: nice.org.uk/guidance/ng256… It recommends offering biopsies to more people with suspected renal cell carcinoma, which could see biopsies rise from around 600 to 1,200 a year, reducing unnecessary surgeries for benign lesions.

"My 3-year-old said, 'You're happy.' I didn't realise I'd disappeared." A hybrid closed loop device helped Ammaarah go from surviving to thriving. Read her story: indepth.nice.org.uk/AmmaarahsJourn…

@MHRAgovuk A huge thanks to all the incredible input of attendees at #NICEConf26. Some closing words from our chief executive, Professor Jonathan Benger⬇️

@MHRAgovuk Our final #NICEConf26 panel explored how our new whole lifecycle approach to guidance will: ✅expand access to cost-effective innovations ✅give clinicians clearer decision pathways ✅and phase out less effective treatments to make room for tomorrow's breakthroughs.

The stage is set for the 2026 NICE Conference. We’ll be exploring ⏩faster access to medicines ⚖️tackling health inequalities 💷and making every NHS pound count. Follow and share your updates throughout the day, using #NICEConf26

Abdominal pain, bloating, feeling full quickly — ovarian cancer symptoms are easy to miss. Recently published draft guidance for suspected cancer proposes new blood test thresholds to help identify those most at risk sooner⬇️ nice.org.uk/news/articles/… #OvarianCancerAwarenessMonth